Bayou City Banks

Houston declared one of the most affordable places to live and work in 2019

Houstonians get to keep a good bit of cash in their pockets. Photo by Jacob Power

A new study indicates it's worth it to live and work in Houston. The study, done by BusinessStudent.com, puts Houston among the country's 25 most affordable places to live and work for 2019.

Four other Texas cities appear ahead of Houston in the report: Fort Worth (No. 7), College Station (No. 18), Irving (No. 21), and Dallas (No. 22). Noticeably absent from the top 25 are Austin and San Antonio.

"Making a high salary is great," BusinessStudent.com points out, "but if rents are so high that you have very little disposable income left over, are you going to be able to put money away for a rainy day?"

"Obviously," the website adds, "a person's individual cultural and social tastes should also be considered, but from a purely financial standpoint, it would be wise to consult this list ... before you begin your next job or home search."

To come up with its list, BusinessStudent.com examined salaries for 100 business-related jobs on Indeed.com and compared them with the average rent of a two-bedroom apartment listed on Rentjungle.com. In the top three positions on BusinessStudent.com's affordability list are Tulsa, Oklahoma; Lexington, Kentucky; and Oklahoma City, Oklahoma.

The study found that in Houston, residents had 79 percent of their salary left after paying rent. That's based on an average annual salary of $79,579 and average monthly rent of $1,401.

Fort Worth residents have it the best in Texas, with 82 percent of their salary left after housing costs, with an average annual salary of $75,797 and rent of $1,108. In College Station, 80 percent of the average salary ($55,086) remained after paying rent ($906 a month).

In Irving, 79 percent of the average annual salary ($77,527) was left after paying rent ($1,327 a month). Dallas had the same share of salary remaining after paying rent (79 percent), but the average salary ($82,609) and average rent ($1,422) were considerably higher than Fort Worth or Irving — and slightly higher than Houston.

------

This story originally appeared on CultureMap.

Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The former CPA had found success in life sciences with a company that sold devices for the treatment of acne. That introduction into the field of medical technology pushed him toward more profound issues than spotty skin.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

The since-deceased Dr. Charles Conrad slowly lured Klemp into what he calls the "cancer ecosphere" of MD Anderson. In 2016, the company went public. And it looks like sooner rather than later, it could make major inroads against some of the toughest cancers to beat.

Klemp observed that while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he says. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

The company has three core technologies currently being tested with some success, but the most promising is called WP1066, named for researcher Waldemar Priebe, "a rock star" in his native Poland, according to Klemp, who works at MD Anderson. Though Priebe came to the U.S. in the 1980s, he is still an adjunct professor at the University of Warsaw and conducts some of his trials in Poland because it's easier to get grant money there.

WP1066 uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The molecular compound that Priebe discovered affects STAT3 (signal transducer and activator of transcription), a transcription factor that encourages tumor development. In short, the active compound in WP1066 both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

WP1066 is demonstrating drug-like properties in trials at MD Anderson on glioblastoma, the aggressive brain cancer that recently took the life of the hospital's former president, John Mendelsohn, as well as John McCain and Beau Biden. It is also being tested against pancreatic cancer, one of the most virulent killers cancer doctors combat.

Priebe also created Annamycin, named for his oldest daughter, a first-line chemotherapy drug that fights Acute Myeloid Leukemia without the cardiotoxicity that can damage patients' hearts even as they beat their cancer.

WP1122 uses yet another mechanism to fight cancer.

"Most people don't know that morphine is essentially a modified version of heroin," Klemp explains.

The difference between the poppy-based drugs? Heroin can cross the blood-brain barrier. It's described as the dicetyl ester of morphine. WP1122 is the dicetyl ester of 2DG (2-Deoxyglucose), a glycolysis inhibitor, which works by overfilling tumor cells with fake glucose so that they can't consume the real glucose that makes them grow.

"The theory is, we could feed you so full of junk food that eventually you'd starve to death," Klemp elucidates. It can cross the blood-brain barrier and is metabolized slowly, meaning that it can be made into a drug in a way that 2DG cannot.

What's impressive about Moleculin is its diversity of drugs. Most companies have one drug that gets all or most of the attention. Moleculin has strong hopes for all three currently in trials.

"It's essentially multiple shots on the goal," says executive vice president and CFO Jonathan Foster.

Moleculin has 13 total employees, five of whom are based in Houston. An office in the Memorial Park area serves as a landing pad for employees and collaborators from around the world to get their work done when in Space City. The virtual office set-up works for the company because experts can stay in their home cities to get their work done. And that work is on its way to saving scores of lives.